Nuclear Pharmacy Market
完整報告名稱與涵蓋範圍
Nuclear Pharmacy Market Size, Share & Trends Analysis Report By Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals), Therapeutic Nuclear Medicine (Alpha Emitters, Beta Emitters), Brachytherapy Isotopes. By Application (Diagnostic Applications (SPECT Applications, PET Applications), Therapeutic Applications), By Region, And By Segment Forecasts, 2025-2034
報告摘要
The Nuclear Pharmacy Market on a global scale was estimated at USD 6.27 Bn in 2024 and is poised to attain USD 17.96 Bn by 2034, with a projected CAGR of 11.2% between 2025 and 2034.
Nuclear Pharmacy encompasses key industry insights & findings from the report:
The market is growing because technological developments have made it possible to diagnose and treat malignant tumours with radiopharmaceuticals. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the mounting emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nuclear Pharmacy Market Snapshot
Chapter 4. Global Nuclear Pharmacy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5. Market Segmentation 1: By Type Estimates & Trend Analysis
5.1. By Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type:
5.2.1. Diagnostic Nuclear Medicine
5.2.1.1. SPECT Radiopharmaceuticals
5.2.1.1.1. Tc-99m
5.2.1.1.2. I-123
5.2.1.1.3. Tl-201
5.2.1.1.4. Ga-67
5.2.1.1.5. Other SPECT Isotopes
5.2.1.2. PET Radiopharmaceuticals
5.2.1.2.1. F-18
5.2.1.2.2. Rb-82
5.2.1.2.3. Other PET Isotopes
5.2.2. Therapeutic Nuclear Medicine
5.2.2.1. Alpha Emitters
5.2.2.1.1. Ra-223
5.2.2.2. Beta Emitters
5.2.2.2.1. I-131
5.2.2.2.2. Y-90
5.2.2.2.3. Sm-153
5.2.2.2.4. Lu-177
5.2.2.2.5. Re-186
5.2.2.2.6. Other Beta Emitters
5.2.3. Brachytherapy Isotopes
5.2.3.1. I-125
5.2.3.2. Ir-192
5.2.3.3. Pd-103
5.2.3.4. Cs-131
5.2.3.5. Other Brachytherapy Isotopes
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Diagnostic Applications
6.2.1.1. SPECT Applications
6.2.1.1.1. Cardiology
6.2.1.1.2. Bone Scans
6.2.1.1.3. Thyroid Applications
6.2.1.1.4. Pulmonary Scans
6.2.1.1.5. Other SPECT Applications
6.2.1.2. PET Applications
6.2.1.2.1. Oncology
6.2.1.2.2. Cardiology
6.2.1.2.3. Neurology
6.2.1.2.4. Other PET Applications
6.2.2. Therapeutic Applications
6.2.2.1. Thyroid Indications
6.2.2.2. Bone Metastasis
6.2.2.3. Lymphoma
6.2.2.4. Endocrine Tumors
6.2.2.5. Other Indications
Chapter 7. Nuclear Pharmacy Market Segmentation 4: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Type, 2021-2034
7.1.2. North America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.1.3. North America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.2.2. Europe Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.2.3. Europe Nuclear Pharmacy Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.3.2. Asia Pacific Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.3.3. Asia Pacific Nuclear Pharmacy Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.4.2. Latin America Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.4.3. Latin America Nuclear Pharmacy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. Middle East & Africa
7.5.1. Middle East & Africa Nuclear Pharmacy Market revenue (US$ Million) by By Type, 2021-2034
7.5.2. Middle East & Africa Nuclear Pharmacy Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
7.5.3. Middle East & Africa Nuclear Pharmacy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1 GE HealthCare
8.2.2 Cardinal Health
8.2.3 Curium
8.2.4 Bayer AG
8.2.5 Lantheus Holdings, Inc.
8.2.6 Bracco Imaging S.p.A.
8.2.7 PharmaLogic Holdings Corp.
8.2.8 Eczacibasi-Monrol Nuclear Products
8.2.9 NTP Radioisotopes SOC Ltd
8.2.10 Nordion Inc.
8.2.11 Novartis (Advanced Accelerator Application)
8.2.12 NorthStar Medical Radioisotopes
8.2.13 Eckert & Ziegler
8.2.14 Isotope JSC
8.2.15 Siemens Healthineers
8.2.16 Jubilant DraxImage,Inc.
8.2.17 Telix Pharmaceuticals Limited
8.2.18 Mallinckrodt Pharmaceuticals
8.2.19 Bracco
8.2.20 IBA Worldwide
8.2.21 Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們